| |
 |
ARTICLES 
|
|
| Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population |
| M Markman and W Hoskins |
|
JCO Apr 1 1992: 513–514.
[PDF]
|
 |
| Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: an old lesson revisited |
| MJ O'Connell |
|
JCO Apr 1 1992: 515–516.
[PDF]
|
|
| Out of the courtroom and into the clinic |
| NE Davidson |
|
JCO Apr 1 1992: 517–519.
[PDF]
|
|
|
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer |
| |
DI Jodrell, MJ Egorin, RM Canetta, P Langenberg, EP Goldbloom, JN Burroughs, JL Goodlow, S Tan, and E Wiltshaw |
| |
JCO Apr 1 1992: 520–528.
[Abstract]
[PDF]
|
|
|
Significance of epidermal growth factor receptor in advanced ovarian cancer |
| |
G Scambia, P Benedetti Panici, F Battaglia, G Ferrandina, G Baiocchi, S Greggi, R De Vincenzo, and S Mancuso |
| |
JCO Apr 1 1992: 529–535.
[Abstract]
[PDF]
|
|
|
Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial |
| |
A Lerner, R Gonin, GD Steele, Jr, and RJ Mayer |
| |
JCO Apr 1 1992: 536–540.
[Abstract]
[PDF]
|
|
|
FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer |
| |
D Kelsen, OT Atiq, L Saltz, D Niedzwiecki, D Ginn, D Chapman, R Heelan, C Lightdale, V Vinciguerra, and M Brennan |
| |
JCO Apr 1 1992: 541–548.
[Abstract]
[PDF]
|
|
|
Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group |
| |
|
| |
JCO Apr 1 1992: 549–557.
[Abstract]
[PDF]
|
|
|
High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol |
| |
CR Nichols, J Andersen, HM Lazarus, H Fisher, J Greer, EA Stadtmauer, PJ Loehrer, and DL Trump |
| |
JCO Apr 1 1992: 558–563.
[Abstract]
[PDF]
|
|
|
Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors |
| |
JF Sturgeon, MA Jewett, RE Alison, MK Gospodarowicz, R Blend, S Herman, H Richmond, G Thomas, W Duncan, and A Munro |
| |
JCO Apr 1 1992: 564–568.
[Abstract]
[PDF]
|
|
|
Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? |
| |
SD Fossa, H Qvist, AE Stenwig, HH Lien, S Ous, and KE Giercksky |
| |
JCO Apr 1 1992: 569–573.
[Abstract]
[PDF]
|
|
|
Long-term effects of chemotherapy in patients with testicular cancer |
| |
S Osanto, A Bukman, F Van Hoek, PJ Sterk, JA De Laat, and J Hermans |
| |
JCO Apr 1 1992: 574–579.
[Abstract]
[PDF]
|
|
|
Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial |
| |
RL Burkes, RJ Ginsberg, FA Shepherd, ME Blackstein, ME Goldberg, PF Waters, GA Patterson, T Todd, FG Pearson, and JD Cooper |
| |
JCO Apr 1 1992: 580–586.
[Abstract]
[PDF]
|
|
|
Curability of solitary bone plasmacytoma |
| |
MA Dimopoulos, J Goldstein, L Fuller, K Delasalle, and R Alexanian |
| |
JCO Apr 1 1992: 587–590.
[Abstract]
[PDF]
|
|
|
Treatment of bone metastases with dichloromethylene bisphosphonate |
| |
G Francini, S Gonnelli, R Petrioli, F Conti, P Paffetti, and C Gennari |
| |
JCO Apr 1 1992: 591–598.
[Abstract]
[PDF]
|
|
|
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma |
| |
DC Allred, GM Clark, AK Tandon, R Molina, DC Tormey, CK Osborne, KW Gilchrist, EG Mansour, M Abeloff, and L Eudey |
| |
JCO Apr 1 1992: 599–605.
[Abstract]
[PDF]
|
|
|
Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study |
| |
R Trueworthy, J Shuster, T Look, W Crist, M Borowitz, A Carroll, L Frankel, M Harris, H Wagner, and M Haggard |
| |
JCO Apr 1 1992: 606–613.
[Abstract]
[PDF]
|
|
|
Late effects of therapy in patients with paratesticular rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee |
| |
R Heyn, RB Raney, Jr, DM Hays, M Tefft, E Gehan, B Webber, and HM Maurer |
| |
JCO Apr 1 1992: 614–623.
[Abstract]
[PDF]
|
|
|
Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study |
| |
MM Wofford, SD Smith, JJ Shuster, W Johnson, GR Buchanan, MD Wharam, AK Ritchey, D Rosen, ME Haggard, and BL Golembe |
| |
JCO Apr 1 1992: 624–630.
[Abstract]
[PDF]
|
|
|
Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia |
| |
F Herrmann, SG Helfrich, A Lindemann, E Schleiermacher, C Huber, and R Mertelsmann |
| |
JCO Apr 1 1992: 631–634.
[Abstract]
[PDF]
|
|
|
Combined modality therapy for primary CNS lymphoma |
| |
LM DeAngelis, J Yahalom, HT Thaler, and U Kher |
| |
JCO Apr 1 1992: 635–643.
[Abstract]
[PDF]
|
|
|
Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission |
| |
LF Verdonck, AW Dekker, GC de Gast, HM Lokhorst, and HK Nieuwenhuis |
| |
JCO Apr 1 1992: 644–646.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor |
| |
EK Rowinsky, LB Grochow, CB Hendricks, DS Ettinger, AA Forastiere, LA Hurowitz, WP McGuire, SE Sartorius, BG Lubejko, and SH Kaufmann |
| |
JCO Apr 1 1992: 647–656.
[Abstract]
[PDF]
|
|
|
High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer [published erratum appears in J Clin Oncol 1992 Oct;10(10):1655-8] |
| |
DM Eddy |
| |
JCO Apr 1 1992: 657–670.
[Abstract]
[PDF]
|
|
| Reassessment of patient response to monoclonal antibody 3F8 |
| NV Cheung, H Lazarus, FD Miraldi, NA Berger, CR Abramowsky, UM Saarinen, T Spitzer, SE Strandjord, and PF Coccia |
|
JCO Apr 1 1992: 671–672.
[PDF]
|
|
| Interferon beta for malignant glioma |
| JG Cairncross and DR Macdonald |
|
JCO Apr 1 1992: 672a.
[PDF]
|
|
| Oncologists and clinical trials: the profit motive |
| TJ Smith and CE Desch |
|
JCO Apr 1 1992: 672b–673.
[PDF]
|
|
| Assessment of cell-cycle effects of cytokines in vivo |
| HD Preisler and A Raza |
|
JCO Apr 1 1992: 673–674.
[PDF]
|
|
